Market Intelligence, Clinical Progress, and High-Purity Reagents for Muscle Wasting, Sarcopenia, and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MSTN (Myostatin/GDF8) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MSTN Mature Domain & Prodomain Recombinant Protein (Pro-Form/Mature) High purity (>95%), HEK293 expressed, Endotoxin <1EU/ug, Sequence Verified. |
View MSTN Products |
| Decoy Receptor | ActRIIB-Fc Fusion Protein Validated competitor for blocking assays; Sequence Verified. |
View ACVR2B Products |
| Gene Delivery | MSTN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and secreted expression. |
View MSTN Products |
| Benchmark Ab | Anti-MSTN (Clinical Benchmark Sequence: Apitegromab/Trevogrumab/Bimagrumab Biosimilars) Recombinant positive control, Sequence Verified. |
View MSTN Products |
| Validator | MSTN siRNA Set For knockdown verification and specificity checks. |
View MSTN Products |
| Related Target A | GDF11/BMP11 High-homology mature domain for selectivity counter-screening. |
View GDF11 Products |
| Related Target B | ActRIIB (ACVR2B) Primary type II receptor for competitive binding and neutralization assays. |
View ACVR2B Products |
| Related Target C | ActRIIA (ACVR2A) Alternative signaling receptor for combinatorial targeting. |
View ACVR2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GDF11 Cross-reactivity & Toxicity | Human/Mouse ortholog GDF11 proteins available with >95% purity for strict SPR counter-screening; homolog panel (Activin A/B) included. |
| Latent vs Mature Conformation | Both Pro-myostatin complex and cleaved mature proteins synthesized with native glycosylation for mechanism-of-action studies. |
| Cross-species Evaluation (Cyno/Mouse) | Human, Mouse, Cynomolgus ortholog proteins available with >95% purity, Sequence Verified. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included as positive controls. |
| False Positives in Signaling Assays | Validated siRNA and neutralizing antibody controls included for specificity checks. |
| High-concentration Sub-Q Stability | Low-endotoxin, high-purity formulations support viscosity and concentration-limit studies. |
Live MSTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MSTN (Myostatin) therapeutics is experiencing a massive resurgence. Historically focused on rare muscle-wasting disorders like Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), major players are rapidly shifting focus to Obesity and Metabolic Syndrome. As GLP-1/GIP receptor agonists induce significant weight loss, the concomitant loss of lean muscle mass has emerged as a critical clinical hurdle. The next wave of R&D is targeting MSTN to preserve skeletal muscle quality during rapid adipose reduction, positioning anti-MSTN therapeutics as the essential companion modality to incretin-based obesity drugs. Additionally, first-generation pan-TGF-beta receptor traps (ActRIIB-Fc) encountered dose-limiting off-target toxicities, accelerating the move toward highly selective anti-MSTN monoclonal antibodies and latent-conformation targeting strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Scholar Rock, Biohaven, Eli Lilly, Regeneron | SMA, Obesity (GLP-1 combo), Sarcopenia | Pro-form Binding Assay (Need high-purity Pro-MSTN complex) & GDF11 selectivity panel |
| Latent-Targeted Antibody | Scholar Rock (Apitegromab) | SMA, Becker Muscular Dystrophy | Conformation-specific binding assay (Need prodomain & mature MSTN proteins) |
| Receptor Decoy (Fc Fusion) | Versanis (Eli Lilly), Acceleron (Merck), Roche | Heart Failure, Obesity, Cancer Cachexia | Ligand Capture & Pan-ligand neutralization panel (Need Mature MSTN, ActRIIB-Fc, Activin A, GDF11) |
| Bispecifics | Various | Muscle Wasting | Selectivity Assay (Need Activin A / MSTN cross-reactive panels) |
| Gene Therapy / RNAi | Regeneron, Alnylam, Various Biotech | Metabolic Syndrome, DMD | Knockdown validation (Need MSTN siRNA and ORF Lentivirus) |